Solitary Fibrous Tumors: Research Advances, Treatment Strategies, and Hope for Sarcoma Patients
3 months ago
- SFT prognosis depends on initial risk level; anti-angiogenics like pazopanib offer better control than chemo, with potential for drug rotation.
- Emerging therapies like tepotinib (alternative splicing inhibition) show promising tumor shrinkage in ongoing phase II trials.
- Patients should engage sarcoma experts, multidisciplinary teams, and advocacy groups for access to innovative research and hope.
Comments